BRAF inhibition in fact induces the formation (by melanoma cells) of a fibronectin-derived protective niche that activates signaling from α5β1 integrin/PI3K/AKT leading to an increase in the expression of the pro-survival myeloid cell leukemia 1 (MCL1) protein that mediates therapeutic escape. Here, AKT1 is linked to melanoma.